New therapeutic agents marketed in 2024: Part 2

Course overview

0202-0000-25-194-H01-P / The FDA approved 50 new drugs in 2024. Seven new therapeutic agents are considered in this review, the second in a two-part series of articles on new therapeutic agents approved in 2024. These new drugs include: vadadustat [Vafseo TM Akebia Therapeutics, Inc.], donanemab-azbt [Kisunla TM Eli Lilly and Company], xanomeline and trospium chloride (Cobenfy TM Bristol Myers Squibb), sofpironium (Sofdra TM Botanix Pharmaceuticals Ltd.), epinephrine Nasal Spray [neffy TM ARS Pharmaceuticals], lebrikizumab lbkz injection [Ebglyss TM Eli Lilly], nemolizumab ilto for Injection [Nemluvio Galderma].